Sacubitril / Valsartan
Common brands: Entresto, Lasix, Coreg, Aldactone, Furosemide
Top reporter: Novartis Pharmaceuticals Corporation
Angiotensin 2 Receptor Blocker [EPC]Loop Diuretic [EPC]Aldosterone Antagonist [EPC]beta-Adrenergic Blocker [EPC]alpha-Adrenergic Blocker [EPC]
114,605
Total Reports
60,584
Serious Reports
14,085
Death Reports
30
Reported Reactions
Death Report Ratio: High (12.29%)
Patient Demographics
Reported Adverse Reactions (30)
Side effects reported in FDA adverse event reports for Sacubitril / Valsartan.
| # | Reaction | Reports | % of Total |
|---|---|---|---|
| 1 | HYPOTENSION | 11,502 | |
| 2 | DEATH | 9,125 | |
| 3 | DYSPNOEA | 8,943 | |
| 4 | DIZZINESS | 8,665 | |
| 5 | FATIGUE | 8,657 | |
| 6 | COUGH | 7,844 | |
| 7 | WRONG TECHNIQUE IN PRODUCT USAGE PROCESS | 7,305 | |
| 8 | WEIGHT DECREASED | 5,191 | |
| 9 | CARDIAC FAILURE | 4,476 | |
| 10 | MALAISE | 4,443 | |
| 11 | ASTHENIA | 3,784 | |
| 12 | WEIGHT INCREASED | 3,503 | |
| 13 | BLOOD PRESSURE DECREASED | 3,155 | |
| 14 | PRODUCT DOSE OMISSION ISSUE | 2,831 | |
| 15 | MYOCARDIAL INFARCTION | 2,770 | |
| 16 | FALL | 2,714 | |
| 17 | INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION | 2,677 | |
| 18 | FEELING ABNORMAL | 2,666 | |
| 19 | DRUG INEFFECTIVE | 2,613 | |
| 20 | CARDIAC DISORDER | 2,562 | |
| 21 | HYPERTENSION | 2,483 | |
| 22 | EJECTION FRACTION DECREASED | 2,478 | |
| 23 | DIARRHOEA | 2,465 | |
| 24 | HYPOACUSIS | 2,357 | |
| 25 | MEMORY IMPAIRMENT | 2,316 | |
| 26 | PERIPHERAL SWELLING | 2,263 | |
| 27 | FLUID RETENTION | 2,259 | |
| 28 | ATRIAL FIBRILLATION | 2,134 | |
| 29 | COVID-19 | 2,104 | |
| 30 | PRODUCT USE IN UNAPPROVED INDICATION | 1,988 |
Important Disclaimer
FDA adverse event reports are submitted voluntarily and do not prove causation. A reported reaction does not mean the drug caused it. Drugs with more users naturally have more reports. Always consult your doctor or pharmacist before making medication decisions.